Neurocrine Biosciences v. Zydus — Valbenazine Patent Case Dismissed Without Prejudice
Neurocrine Biosciences filed suit in Delaware against Zydus Cadila and related entities asserting 17 patents covering valbenazine formulations, VMAT2 inhibitor methods, and related compounds. The case ran for 591 days before the parties jointly stipulated to dismiss all claims, counterclaims, and affirmative defenses without prejudice and without costs to any party.
17-Patent Valbenazine Dispute Ends in No-Cost Mutual Dismissal
On 1 April 2022, Neurocrine Biosciences, Inc. filed an infringement action in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-00439) before Judge Maryellen Noreika. The complaint asserted 17 U.S. patents against Zydus Cadila, Zydus Lifesciences Limited (f/k/a Cadila Healthcare Limited), Zydus Worldwide DMCC, and ZY Holdings, LLC, covering high-dosage valbenazine formulations, VMAT2 inhibitor administration methods, substituted hexahydro-pyrido-isoquinoline compounds, and valbenazine salts and polymorphs.
The case closed on 13 November 2023. The recorded basis of termination is 'Dismissed without Prejudice.' The docket order reflects a stipulation filed under Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), by which the parties agreed that all claims, counterclaims, and affirmative defenses are dismissed without prejudice and without costs, disbursements, or attorneys' fees to any party. The stipulation further notes that the District of Delaware retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions.
The case resolved at 591 days — within the range commonly seen for complex ANDA-adjacent pharmaceutical patent disputes — without proceeding to trial or a publicly reported Markman ruling. The absence of a merits adjudication and the without-prejudice framing mean Neurocrine retains the right to re-assert these patents. The specific commercial or licensing terms, if any, underlying the parties' resolution are not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 591 days
591 days from filing to dismissal — typical ANDA patent cases in Delaware often resolve in 18–30 months
US10851104B2 — High-dosage valbenazine formulations and VMAT2 inhibitor patents
Any pharmaceutical company, generic manufacturer, or 505(b)(2) filer considering a valbenazine product — including VMAT2 inhibitor formulations, dosing methods, or related compound chemistry — should treat all 17 patents asserted in this case as live enforcement risk. The without-prejudice dismissal means none of these patents have been adjudicated invalid or not infringed. Product and regulatory teams planning Orange Book certifications or ANDA filings in this space face a dense, multi-patent FTO challenge with no prior claim construction record to rely on.
Official order — verbatim text
The parties' joint stipulation under FRCP 41(a)(1)(A)(ii) and 41(c) terminates all claims and counterclaims without prejudice and without any cost liability, consistent with the recorded basis of termination. No merits determination — on infringement, validity, or claim construction — was reached on any of the 17 asserted patents. The court's retained jurisdiction to resolve disputes relating to 'the parties' resolution' suggests the existence of an underlying agreement, though its terms are not disclosed in the available record.
Dismissed without prejudice: what the stipulated resolution means for both parties
Rule 41 stipulated dismissal without prejudice
The parties invoked FRCP 41(a)(1)(A)(ii) and 41(c) to jointly dismiss all claims, counterclaims, and affirmative defenses. A dismissal without prejudice under Rule 41 is not a final adjudication on the merits — it extinguishes the current action but does not bar future litigation on the same patents. The court retains jurisdiction to enforce the parties' resolution, suggesting some form of underlying agreement, though its specific terms are not disclosed in the available record.
No merits adjudicationNeurocrine preserves all 17 patents for future enforcement
Because the dismissal is without prejudice, Neurocrine Biosciences is not barred from re-asserting any of the 17 patents in future proceedings. The company's VMAT2 inhibitor and valbenazine patent portfolio remains intact and enforceable. No adverse claim construction, invalidity ruling, or damages finding was entered against any of the asserted patents. Neurocrine also bears no costs under the stipulation.
Patents remain enforceableZydus entities exit this action without a merits ruling
All four Zydus entities — Zydus Cadila, Zydus Lifesciences Limited, Zydus Worldwide DMCC, and ZY Holdings, LLC — are dismissed from the action without prejudice and without any cost liability. No infringement finding or validity ruling was entered against them. However, the without-prejudice nature of the dismissal means the threat of future litigation on these 17 patents is not eliminated. The underlying resolution terms are not disclosed in the available record.
No infringement findingGeneric valbenazine entry remains uncertain
With 17 patents dismissed without prejudice rather than invalidated or adjudicated, the commercial pathway for Zydus to launch a generic or competing valbenazine product remains legally uncertain. Competitors and product teams in the VMAT2 inhibitor space should note that Neurocrine's patent portfolio is substantively undiminished by this outcome. Any party considering entering this therapeutic area should treat these 17 patents as live enforcement risk until a merits ruling or confirmed expiry.
Generic pathway uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Neurocrine Biosciences, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | /Search in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Zydus Worldwide DMCC | Individual | Search in Eureka ↗ |
| Co-Defendant | ZY Holdings, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Phillips, Goldman, McLaughlin & Hall PA | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the VMAT2 inhibitor and valbenazine patent space
Forward-looking patent intelligence on Neurocrine's valbenazine portfolio, Zydus's VMAT2 competitive posture, and white-space opportunities in the VMAT2 inhibitor and tardive dyskinesia therapeutic domain.
Neurocrine's VMAT2 patent filing depth and continuation activity
Neurocrine's 17-patent cluster in this case — spanning applications filed across 2019–2020 — suggests an active continuation prosecution strategy around valbenazine. Monitoring Neurocrine's downstream continuation and divisional filings from these application families will reveal where the company is seeking to extend coverage, particularly into new formulation strengths, administration routes, or patient subpopulation methods.
Continuation watchVMAT2 inhibitor patent filing trends in tardive dyskinesia
The VMAT2 inhibitor space — covering tetrabenazine, deutetrabenazine, and valbenazine analogues — has seen concentrated patent activity from a small number of originators. Tracking filing trends around VMAT2 inhibitor compound chemistry, dosing regimens, and salt forms reveals where the next wave of innovation and potential conflict may emerge for movement disorder therapeutics.
VMAT2 landscape activeZydus Lifesciences patent activity in CNS and movement disorder drugs
Zydus Lifesciences is an active generic and specialty pharmaceutical filer. Monitoring its patent applications and ANDA filings in the CNS and movement disorder space — particularly any independent compound or formulation patents that could support a future valbenazine generic strategy — provides early signal of renewed competitive entry planning following this dismissal.
Generic entry signalsAdjacent compound and delivery innovation near valbenazine chemistry
The hexahydro-pyrido-isoquinoline scaffold at the core of valbenazine presents potential white-space opportunities in modified release formulations, novel salt forms not covered by existing Neurocrine patents, and combination therapy methods. R&D teams exploring VMAT2-adjacent CNS targets may find claim space in these adjacent areas less densely populated by existing Neurocrine filings.
Formulation white spaceSimilar VMAT2 inhibitor and valbenazine patent cases in Delaware
Explore comparable ANDA-related pharmaceutical patent infringement actions in Delaware District Court involving VMAT2 inhibitors, CNS formulation patents, and multi-patent dismissal outcomes.
What this case signals for the VMAT2 inhibitor IP landscape
Seventeen patents, no merits ruling, and a without-prejudice dismissal — this case leaves the valbenazine IP landscape materially unchanged for competitors.
A without-prejudice dismissal is not patent clearance
Generic manufacturers and biosimilar entrants sometimes misread Rule 41 dismissals as market clearance. Here, all 17 Neurocrine patents survive fully enforceable. Companies conducting FTO analysis for valbenazine or related VMAT2 inhibitors must treat each of these patents as live risk until a validity or non-infringement ruling is obtained.
Court-retained jurisdiction signals a structured resolution
The stipulation expressly preserves Delaware jurisdiction to enforce 'the parties' resolution.' This language is consistent with some form of underlying agreement between the parties, though the specific terms are not disclosed in the available record. IP counsel monitoring this space should track any subsequent Delaware filings that may surface enforcement or compliance disputes.
Neurocrine v Zydus — key questions answered
The case was dismissed without prejudice. On 13 November 2023, the parties filed a joint stipulation under FRCP 41(a)(1)(A)(ii) and 41(c) dismissing all claims, counterclaims, and affirmative defenses without prejudice and without costs, disbursements, or attorneys' fees to any party. No merits ruling was entered on any of the 17 asserted patents.
Neurocrine asserted 17 U.S. patents, including US10851104B2, US11026931B2, US10906902B2, US11040029B2, US10851103B2, US10919892B2, US10874648B2, US10844058B2, US10857137B2, US10912771B1, US11026939B2, US10952997B2, US10940141B1, US10906903B2, US10993941B2, US10857148B2, and US15338214. The patents cover valbenazine formulations, VMAT2 inhibitor methods, compound chemistry, and salts and polymorphs.
Not necessarily. A dismissal without prejudice does not constitute a finding of invalidity or non-infringement. All 17 Neurocrine patents remain enforceable, and Neurocrine retains the right to re-assert them in future proceedings. Any Zydus generic valbenazine launch would still need to address these patents — through Paragraph IV certification, design-around, or further litigation.
The stipulation expressly states that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions. This language is consistent with some form of underlying agreement between the parties, though the specific terms are not disclosed in the available record.
The case ran for 591 days from filing on 1 April 2022 to closure on 13 November 2023 — approximately 19.7 months. This duration is broadly consistent with the range seen in complex pharmaceutical patent cases in the District of Delaware, which frequently involve extended discovery and claim construction schedules before any trial date.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.